Menopur Injection contains Menotrophin (75 IU), a purified preparation of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) derived from the urine of postmenopausal women. It is indicated for use in assisted reproductive technologies, including controlled ovarian stimulation in women undergoing in vitro fertilization (IVF) or other assisted reproductive procedures. Menopur facilitates the development and maturation of multiple ovarian follicles by stimulating follicular growth, thereby increasing the chances of successful ovulation and fertilization. The dosage and duration of treatment are individualized based on patient response, monitored through ultrasound and serum estradiol levels to minimize the risk of ovarian hyperstimulation syndrome (OHSS). Menopur is administered via subcutaneous or intramuscular injection, with reconstitution required prior to use. Common adverse effects include injection site reactions, headache, abdominal discomfort, and ovarian enlargement. Caution is advised in patients with ovarian cysts, hormone-sensitive tumors, or hypersensitivity to gonadotropins. Menopur should be used under strict medical supervision with appropriate monitoring to optimize therapeutic outcomes and reduce potential complications. It is contraindicated in pregnancy, primary ovarian failure, and uncontrolled thyroid or adrenal dysfunction. This product is intended solely for use in fertility treatment protocols.